CV: bradycardia, edema, orthostatic hypotension, thromboembolic events (↑ risk with dexamethasone in multiple myeloma).
Derm: drug reaction with eosinophilia and systemic symptoms (dress), rash, stevens-johnson syndrome, toxic epidermal necrolysis, photosensitivity.
GI: constipation.
Hemat: neutropenia, thrombocytopenia.
Neuro: dizziness, drowsiness, peripheral neuropathy, seizures.
Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA), TUMOR LYSIS SYNDROME.
Erythema Nodosum Leprosum
- PO (Adults
50 kg): 100–300 mg once daily initially; up to 400 mg/day has been used, depending on previous response. Every 3–6 mo, attempts should be made to taper and discontinue in decrements of 50 mg every 2–4 wk. - PO (Adults <50 kg): 100 mg once daily initially; up to 400 mg/day has been used, depending on previous response. Every 3–6 mo, attempts should be made to taper and discontinue in decrements of 50 mg every 2–4 wk.
Multiple Myeloma
- PO (Adults): 200 mg once daily in 28-day treatment cycles.
Therapeutic Classification: Immunosuppressant agents
Absorption: 67–93% absorbed following oral administration.
Distribution: Well distributed to tissues.
Metabolism/Excretion: Hydrolyzed in plasma to multiple metabolites. Primarily excreted in the urine (92%; <4% as unchanged drug).
Half-life: 5–7 hr.